Dr. Torsten Neuefeind
CEO
Under Torsten’s guidance, the business has grown to serve most of the Top20 Big Pharma Companies, numerous midsize Pharma and more than 200 Biotech and virtual Biotech companies with a strong presence in the US, including a partnership with a US Venture Capital firm, resulting in a successful exit of a jointly funded company, worth several hundred million ‘Bio-Dollars’.
Peter Persigehl PhD, COO
Peter leads Operations at Proteros and comes to us after growing and scaling operations groups at leading global companies. Most recently, Peter held progressively growing leadership positions, and finally as COO at Eurofins Genomics, a global provider of genomics services, and part of the Eurofins Scientific Group. Prior to that he held leadership positions at Lanxness, a global specialty chemicals company.
Peter trained as an organic chemist, and received his PhD at the Technical University of Munich.
Amar Thyagarajan PhD, CCO
Amar leads the commercial function at Proteros and comes to us after growing and scaling several life science services companies to profitable growth. Most recently, he was he was Global Head of Strategy and Head of Business Development for Aragen Life Sciences’ Biology division, a global provider of preclinical drug discovery solutions. Prior to that he held several leadership positions at Crown Biosciences and Taconic Biosciences, all global life science drug discovery service organizations.
Amar trained as a cell biologist and biochemist, and received his PhD at the State University of New York, followed by a post-doctoral fellowship at MIT.
Prof. Eric P. Pâques
Eric P. Pâques is Non-Executive Chairman of the Supervisory Board of Proteros Biostructure GmbH (Munich, Germany) since 2014, chairman of the Board of Directors of Novadip Biosciences (Belgium) and Board member of Epics Therapeutics (Belgium) and of PL Bioscience (Germany) as well as of several academic and charity organizations. He was Independent Director of INC Research Inc., later Syneos Health, (USA), and Vice-Chairman of the Supervisory Board of the Grünenthal Group (Germany). He served more than 35 years in management positions in the pharmaceutical industry, thereof 20 years as General Manager / CEO of the Grünenthal Group. He is professor at the RWTH-Aachen University (Germany) and holds a Master degree and a PhD in Chemistry (University of Louvain, Belgium).
DANIEL SPASIC
Daniel Spasic is a driven life science entrepreneur with 25 years in senior life science executive roles. He founded TFS International (TFS) in 1996, which became a world-leading midsized global clinical CRO. Under Daniel Spasic's leadership the business grew to $100 million in revenues employing 800+ professionals and serving 250 biopharma and medtech customers worldwide. Daniel Spasic’s expertise covers biopharma- and healthcare services, and he provides advice and guidance in areas such as; strategic positioning, growth enabling initiatives, partnership alliances, venture- and growth funding.
Caspar Graf Stauffenberg
Caspar Graf Stauffenberg is Managing Partner at Carlsquare, a M&A advisory company, where he heads the life sciences and health sector team. He studied Business Administration in Reutlingen (Germany) and London. Subsequently he has worked as project leader at Arthur D. Little in the business area Strategy and Organization and also as project leader Merger & Acquisitions at the Binding Group (today: Radeberger). Before he came to Carlsquare, he has been engaged as initially CFO and subsequently CEO for the MAP Medizin Technologie GmbH as well as CEO and Co-Founder of the Aequos Endoprothetik GmbH. Both such companies have been divested under his leadership.